

# CAREB


## Commodity Action Report & Eps Bulletin

**Contract Name:** Icatibant and C1 Esterase Inhibitor

**Contract Reference:** NP48918

Hazel Johnstone  
Commodity Manager  
National Procurement

26 June 2018



## Document Information

Contract Name: Icatibant and C1 Esterase Inhibitor

Contract Reference: NP48918

National Spend: £986,910

Savings Opportunity: Nil

Start Date: 1 July 2018

Expiry Date: 30 June 2019

Contract Manager: Hazel Johnstone

Tel : GRO-C

Email: Hazel.johnstone@GRO-C

CPV Code : 33600000

## Awarded Supplier (see main text for details of selection and evaluation process)

CSL Behring UK Ltd, Pharming Group and Shire Pharmaceuticals Ltd

## Key Strategy (see main text for further details)

Collaborating with NHS England Commercial Medicines Unit (CMU) on a range of 'blood related' frameworks ensures price parity with the rest of the UK without jeopardising relationships with suppliers and stakeholders. It also maximises efficiency by allowing PCF staff to concentrate on new areas of spend.

Health Board	No Change Impact	Specific HB Comment
Ayrshire & Arran	-£450	No savings have been achieved due to a cost increase from CSL Behring for the supply of Berinert®, resulting in a cost increase £113,850.
Borders	-£600	
Dumfries & Galloway	-	
Fife	-£1,575	
Forth Valley	-	
Grampian	-£525	
Greater Glasgow & Clyde	-£108,675	
Highland	-£375	
Lanarkshire	-£1500	
Lothian	-£150	
NWTC (Golden Jubilee)	-	
Orkney	-	
Shetlands	-	
Western Isles	-	
Special HBs	n/a	
Tayside	-	
<b>Total</b>	<b>-£113,850</b>	

<b>C A R E B</b> National Procurement	<b>Icatibant and C1 Esterase Inhibitor</b>	<b>NP48918</b>
--	--	----------------

## Table of Contents:

1. Introduction.....	4
2. Current Position .....	4
3. New Contract Process and Award .....	5
4. Base Data Used For Contract Analysis and Benefit Calculation.....	6
5. Financial Impact .....	6
6. Details of Opportunity & Method of Call Off.....	7
7. Next Steps .....	8
8. Contract Extensions.....	8

## 1. Introduction

This framework is for the supply of Icatibant (Firazyr®) and the three (3) C1 Esterase brands, Berinert®, Cinryze® and Ruconest® for the treatment of Hereditary Angioedema (HAE). The framework has been awarded by the NHS England (NHSE) Commercial Medicines Unit (CMU) and allows access to contract pricing for all Scottish health boards.

Shire Pharmaceuticals have manufactured commissioned homecare for Firazyr® which has been reviewed and agreed by NHS Scotland Medicines Homecare National Governance and Management Group on for a 'once for Scotland' basis. There is no formal homecare agreement for the remaining products, although the potential to add them to the new NHS commissioned Homecare framework being progressed by PCF may be possible.

## 2. Current Position

NHSE CMU has a framework agreement for the supply of Icatibant and c1-esterase inhibitor that is due to expire 30 June 2018.

NHSS health boards were not listed within the list of participating authorities when this framework was advertised, however NHSS have benefited from the framework pricing due to an informal agreement with suppliers that NHSS would receive price parity for these products for the duration of the CMU framework.

A PAS agreement is in place across NHSS for Icatibant (Firazyr®), PAS Ref 017.

The current spend across all products is £873,060. This has been calculated based on supplier sales data received for the latest 12 month period at current prices. Details of spend by health board and product are shown in table 1 below.

Health Board	Berinert	Cinryze	Firazyr	Total
NHS Ayrshire & Arran	£2,400	£0	£5,975	£8,375
NHS Borders	£3,200	£0	£0	£3,200
NHS Dumfries & Galloway	£0	£0	£0	£0
NHS Fife	£8,400	£0	£0	£8,400
NHS Forth Valley	£0	£0	£0	£0
NHS Grampian	£2,800	£86,625	£3,585	£93,010
NHS Greater Glasgow & Clyde	£579,600	£0	£108,736	£688,336
NHS Highland	£2,000	£0	£0	£2,000
NHS Lanarkshire	£8,000	£0	£1,195	£9,195
NHS Lothian	£800	£0	£37,042	£37,842
NHS Orkney	£0	£0	£0	£0
NHS Shetland	£0	£0	£0	£0
NHS Tayside	£0	£0	£22,703	£22,703
<b>Totals</b>	<b>£607,200</b>	<b>£86,625</b>	<b>£179,235</b>	<b>£873,060</b>

Table 1 Current Spend



Figure 1 below provides a breakdown of current spend by hospital and homecare.




Figure 1 Current Spend by Health Board

### 3. New Contract Process and Award

NHSE CMU have managed the procurement process with engagement from the HAE Procurement Group, which is made up of stakeholders such as Immunologists, Commissioners and patient representatives from HAE UK. NHSS were represented during the tender process by Dr. Richard Herriot, Clinical Group Co-ordinator Consultant from NHS Grampian and PCF Strategic Sourcing.

Table 2 below shows the agreed structure of the framework agreement and the criteria used to evaluate tender responses:

Contracting Process	Agreed Structure
Duration of Framework Agreement	12 Months
Extension Option	Up to 36 months
Selection Criteria	Mandatory Requirements
Evaluation Criteria	Price 70% Security of Supply 20% Ease of Use 5%

Table 2 – Framework Structure

#### Award

It was agreed during the Award of Business CAP that three (3) suppliers would be awarded to the Framework Agreement as detailed below in table 3.

Product	Brand	Supplier	% of total market	Current Price (per IU/ mg)	New Price (Per IU/mg)	Price Difference	Plasma Derived or Recombinant	Rank Position
Icatibant	Firazy®	Shire Pharmaceuticals Ltd	100%	£39.83	£39.83	0%	Recombinant	n/a
C1 Esterase	Cinryze®	Shire Pharmaceuticals Ltd	29.73%	£1.05	£1.05	0%	PD	1
	Ruconest®	Pharming Group	90.80%	n/a	£0.32	n/a	Recombinant	2
	Beriner®	CSL Behring	90.54%	£0.80	£0.95	19%	PD	3

Table 3 Award Details

C1 Esterase Inhibitor

The outcome for C1 Esterase has placed the most commonly used product in NHSS (Berinert®) as 3<sup>rd</sup> ranked; however there are recognised factors, as explained below that will support the continued use of Berinert® to meet clinical requirements.

- 1<sup>st</sup> ranked - Cinryze® - Shire Pharmaceuticals are only able to supply 29.73% of the UK market, therefore not all health boards / trusts will be able to access this medicine.
- 2<sup>nd</sup> ranked - Ruconest® - This is a new product with limited 'real world' clinical data. This is a recombinant product rather than plasma derived, therefore this is not a direct equivalent to the current incumbent product, Berinert®. The introduction of Ruconest® offers a suitable product for a small group of people belonging to the religious group, Jehovah's Witness, as they do not accept blood transfusion or blood products.
- 3<sup>rd</sup> ranked - Berinert® - There is not expected to be any supply issues based on current NHSS usage figures and therefore current patients can remain on Berinert®.

Stakeholder Feedback / NHSE Commissioning Advice

The stakeholder group agreed that reliance on one product was to be avoided to reduce risk and increase security of supply.

However, due to limited product availability, NHSE commissioning advice is Cinryze® should be prioritised for prophylactic use, and therefore no new patients will be put on Cinryze® due to limited availability.

Use of Ruconest® is encouraged to increase market share and spread demand and contribute to the collation of 'real world' clinical data.

Clinicians should select the best value product to meet prescribing requirements and supplier's ability to supply based on available volumes provided by the suppliers.

The award information has been shared with Consultant Immunologists in Edinburgh, Glasgow and Dundee to raise awareness of the new framework.

Product details are contained within Appendix 1 – Contract Summary and CCM will be updated prior to the commencement of the Framework on 1 July 2018.

**4. Base Data Used For Contract Analysis and Benefit Calculation**

The base data used to calculate the tender outcome is from supplier sales data and current pricing for the latest twelve (12) months period (CSL Behring May 2017 to April 2018 and Shire June 2017 to May 2018).

The new value of awarded lines on this Framework Agreement has been calculated at £986,910. Further details are contained within the attached Appendix 2 – Health Board Breakdown V01.0 (Final) breakdown.

**5. Financial Impact**

This award has resulted in an overall net cost increase of £113,850 for NHS Scotland due to a cost increase from CSL Behring for the supply of Berinert®, compared against current usage volumes.

The health board breakdown of new spend is shown in table 4 below:



Health Board	Current Spend	New Spend	Financial Impact
NHS Ayrshire & Arran	£8,375	£8,825	-£450
NHS Borders	£3,200	£3,800	-£600
NHS Dumfries & Galloway	£0	£0	£0
NHS Fife	£8,400	£9,975	-£1,575
NHS Forth Valley	£0	£0	£0
NHS Grampian	£93,010	£93,535	-£525
NHS Greater Glasgow & Clyde	£688,336	£797,011	-£108,675
NHS Highland	£2,000	£2,375	-£375
NHS Lanarkshire	£9,195	£10,695	-£1,500
NHS Lothian	£37,842	£37,992	-£150
NHS Orkney	£0	£0	£0
NHS Shetland	£0	£0	£0
NHS Tayside	£22,703	£22,703	£0
<b>Totals</b>	<b>£873,060</b>	<b>£986,910</b>	<b>-£113,850</b>

Table 4 Health board breakdown

## 6. Details of Opportunity & Method of Call Off

### Opportunity

There are no additional opportunities identified for Firazyr® as this is sole supply with no competition.

Due to the introduction of Ruconest®, there may be additional opportunities (subject to clinical suitability) for current patients receiving Berinert® or Cinryze®, however this is unknown at this stage. NP will liaise with health boards to review the opportunities that may be available after the framework start date.

Details of the cost of treatment based on different patient weights are contained within Appendix 3 of the attached CMU Briefing Note.



Appendix 3 - CMU  
Briefing Note 2018 v2

### Method of Call Off

For Icatibant (Firazyr®) the method of call off is directly with the awarded supplier via their nominated distribution route(s), including via the manufacturer commissioned homecare service.

For C1 Esterase Inhibitor the method of call off will be based on local assessment of clinical needs and in accordance with ranked position, taking into account NHSE commissioning advice as explained in Section 3 above. Call off will be via the suppliers nominated distribution route(s), including any homecare arrangements where applicable.

Homecare: Shire Pharmaceuticals have manufactured commissioned homecare for Firazyr® which has been reviewed and agreed by NHS Scotland Medicines Homecare National Governance and Management Group on for a 'once for Scotland' basis. There is no formal homecare agreement for the remaining products, although the potential to add them to the new NHS commissioned Homecare framework being progressed by PCF may be possible.

Further information health boards may find useful can be found in the Appendices within the attached CMU Briefing Note.

<b>C A R E B</b> National Procurement	<b>Icatibant and C1 Esterase Inhibitor</b>	<b>NP48918</b>
--	--	----------------

## 7. Next Steps

Where there is no change to current practise health board procurement leads should update systems and place orders via nominated supply route from 1 July 2018.

Health board procurement leads are advised to liaise with clinical colleagues and review current practice to determine if potential switching of products as detailed in section 6 can be achieved. Health boards are requested to feedback any opportunities to Hazel Johnstone, Commodity Manager at NP.

NP will share the outcome of this award with the NHS Scotland Medicines Homecare National Governance and Management Group for awareness and their consideration of whether there is scope to include these products within the upcoming national NHS commissioned homecare service framework.

Health boards should review any local homecare arrangements in place for C1 esterase to ensure the service provider is aware of new pricing where applicable.

CMU will collect usage data on all products that will be analysed and used to inform any opportunities and future tender demand requirements.

If you have any queries relating to this framework, do not hesitate to contact Hazel Johnstone, Commodity Manager, NHS National Procurement, [hazel.johnstone@GRO-C](mailto:hazel.johnstone@GRO-C) or Tel: **GRO-C**

## 8. Contract Extensions

The framework has the option to extend by up to thirty six (36) months.

### Version History

Version	Date	Revised By	Description	Filename
1.0	26 June 2018	Hazel Johnstone	C A R E B - Icatibant and C1 Esterase	NP48918 CAREB V01.0 (Final)
1.1	26 June 2018	Hazel Johnstone	C A R E B - Icatibant and C1 Esterase	NP48918 CAREB V01.1 (Final)

### Distribution

To	Action	Date
Directors of Pharmacy / Chief Pharmacists	Cascade Distribution to appropriate users	26 June 2018
Dr. Richard Herriot, Clinical Group Co-ordinator Consultant, NHS Grampian	Cascade Distribution to appropriate users	26 June 2018
POG	Cascade Distribution to appropriate users	26 June 2018
Pharmacy Procurement Staff	For Implementation and Logistics	26 June 2018